Corrole nanobiologics for targeting resistant and metastatic tumors

Corrole 纳米生物制剂用于靶向耐药性和转移性肿瘤

基本信息

批准号：
10241418
负责人：
LALI K MEDINA-KAUWE
金额：
$ 41.56万
依托单位：
CEDARS-SINAI MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
2009
资助国家：
美国
起止时间：
2009-07-01 至 2022-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10241418
关键词：
4T1 Address Adjuvant Agreement Alkanesulfonates Antibodies Binding Biodistribution Biological Markers Blood - brain barrier anatomy Blood Vessels Brain Brain Neoplasms Breast Breast Cancer Model Breast Cancer Treatment Breast cancer metastasis Caliber Cell Communication Cell Nucleus Cell Survival Cell membrane Cell surface Cells Clinic Combined Modality Therapy Cytoplasm Diagnostic Dimerization Directed Molecular Evolution Dose EGF gene EGFR inhibition ERBB2 gene ERBB3 gene Endocytosis Endosomes Endothelium Epidermal Growth Factor Receptor Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Exhibits Funding Gallium Growth Growth Factor HER2 inhibition Heart Heterodimerization Heterogeneity Home Homeostasis Homing Hour Human Image Immunocompetent In Vitro Inbred BALB C Mice Ligand Binding Liver Lytic Macrocyclic Compounds Maintenance Mammary Neoplasms Mediating Membrane Metastatic breast cancer Metastatic malignant neoplasm to brain Mitochondria Modeling Mus Neoadjuvant Therapy Neoplasm Metastasis Neuraxis Neuregulins Nude Mice Patients Penetration Peripheral Pertuzumab Primary Neoplasm Property Proteins Recurrence Recycling Regimen Resistance Resistance development Serum Signal Transduction Specificity Supporting Cell Surface Technology Testing Tissues Toxic effect Trastuzumab Treatment Efficacy Tumor Cell Line Ursidae Family Variant Water Xenograft procedure cell growth chemotherapy combat corrole cytotoxic cytotoxicity direct application immunogenicity improved in vivo individual response inhibitor/antagonist insight lapatinib nanobiologic nanoparticle neoplastic cell neural growth novel particle pressure prevent public health relevance receptor receptor binding receptor downregulation small molecule inhibitor targeted treatment trafficking transcytosis triple-negative invasive breast carcinoma tumor uptake

项目摘要

DESCRIPTION: The majority of tumor-targeted therapies currently used in the clinic are comprised of antibodies or small molecule inhibitors aimed at blocking growth signaling. However, signal-blocking therapies have been ineffective in a majority of cases due to mechanisms that sustain signaling in the face of targeted treatment, highlighting a need for alternative strategies that do not rely on signal-modulation. In our previously funded project, we developed self-assembling protein-corrole constructs that circumvent the need to modulate signaling by using tumor cell surface biomarkers as portals for the targeted entry of corrole molecules. Sulfonated corroles are water soluble, macrocyclic compounds that may be metallated, spontaneously assemble with proteins, and can be cytotoxic as well as bear various photophysical properties for both imaging and diagnostics. We have shown that sulfonated corroles are membrane-impermeable yet require cytoplasmic entry to elicit cytotoxicity while remaining excluded from the nucleus. Our targeted cell penetration protein, HerPBK10, enables corrole uptake into human epidermal growth factor receptor subunit- 2 positive (HER2+) tumors via specific interaction with the HER2 dimerization partner, HER3, which is particularly represented on these cells. Receptor-binding triggers rapid endocytosis followed by endosomal escape via a membrane-lytic domain on HerPBK10, enabling corrole entry into the cytoplasm. The tumor- homing nanoparticle, HerGa, formed by assembly of HerPBK10 and a gallium metallated corrole (S2Ga or Ga- corrole), can target and ablate HER2+ tumors in mice at >10x lower dose compared to conventional chemotherapy while sparing heart and liver tissue, and with no detectable immunogenicity. Studies in recent years have now discovered that elevated cell surface levels of HER3 is associated with resistance to a number of signal-blocking breast cancer treatments, including inhibitors of EGF-R or HER1 (lapatinib), HER2 (lapatinib, trastuzumab, T-DM1), HER2-3 (pertuzumab), and combination therapy. Moreover, HER3 elevation has been identified on metastatic breast tumors, including those that spread to the brain, and on "untarget-able" tumors such as triple-negative breast cancer (TNBC), including TNBC with acquired resistance to EGF-R inhibition. The HER3 specificity of HerPBK10 predicts that tumor cells resisting these signal-blocking treatments are prime targets for HerPBK10-directed nanobiologics. The present study will explore this on models of resistant and metastatic breast cancer, especially those that metastasize to the brain. A regimen of using EGFR and HER2 inhibitors as adjuvants to sensitize tumors to corrole nanobiologics will be evaluated. As the median survival of patients with metastatic breast cancer is 3 years, and patients with breast cancer metastases to the brain on average survive less than one year, improved alternatives are urgently needed.

描述：目前在临床中使用的大多数靶向肿瘤靶向疗法都是旨在阻断生长信号传导的抗体或小分子抑制剂。然而，由于面对靶向治疗的机制维持信号传导，信号阻滞疗法在大多数情况下一直无效，这突出了不依赖信号调节的替代策略的需求。在我们以前资助的项目中，我们开发的自组装蛋白座构建体，通过使用肿瘤细胞表面生物标志物作为孔罗莱斯分子的靶向进入来调节信号传导的需求。磺化的腐病是水溶性，大环化合物，可能是金属化，赞助的，并且可以具有细胞毒性，并且具有各种成像和诊断性的光物理特性。我们已经表明，磺化的腐病是可膜的，但需要细胞质进入才能引起细胞毒性，同时仍排除在核us中。我们的靶向细胞渗透蛋白HERPBK10通过与HER2二聚伴侣HER3的特定相互作用，可以摄取腐蚀性的人表皮生长因子受体亚基2阳性（HER2+）肿瘤，该肿瘤在这些细胞上尤其表示。受体结合会触发快速的内吞作用，然后通过HERPBK10上的膜晶状体结构域内体逸出，从而使孔罗尔进入细胞质。由Herpbk10组装和镀金金属孔（S2GA或GA-CRORE）组装的肿瘤 - 纳米颗粒，Herga，可以靶向和消融小鼠的剂量和剂量较低的剂量，而与传统的化学疗法相比，可以靶向和消融小鼠的HER2+肿瘤，而没有进行传统的心脏和肝脏组织，并且没有可检测的免疫原性。近年来的研究现已发现，HER3的细胞表面水平升高与对许多信号障碍乳腺癌的抗性有关，包括EGF-R或HER1（Lapatinib），Her2（Lapatinib，Trastuzumab，t-DM1），HER2-3（Her2-3（Pertuzumab）和组合疗法的抑制剂。此外，在转移性乳腺肿瘤（包括传播到大脑的乳腺肿瘤）以及“不可靶向”肿瘤（例如三阴性乳腺癌（TNBC））上已经确定了HER3升高，包括对EGF-R抑制的抗性TNBC。 HERPBK10的HER3特异性预测肿瘤细胞抵抗这些信号障碍物是HERPBK10定向纳米生物学的主要靶标。本研究将在抗性和转移性乳腺癌的模型上探讨这一点，尤其是那些转移到大脑的模型。将评估使用EGFR和HER2抑制剂作为对敏感肿瘤的调节剂的方案。由于转移性乳腺癌患者的中位生存期为3年，并且平均生存期乳腺癌转移患者少于一年，因此迫切需要改善的替代方法。

项目成果

期刊论文数量（23）

专著数量（0）

科研奖励数量（0）

会议论文数量（0）

专利数量（0）

A chemokine regulatory loop induces cholesterol synthesis in lung-colonizing triple-negative breast cancer cells to fuel metastatic growth.

DOI：
10.1016/j.ymthe.2021.07.003
发表时间：
2022-02-02
期刊：
Molecular therapy : the journal of the American Society of Gene Therapy
影响因子：
0
作者：
Han B;Alonso-Valenteen F;Wang Z;Deng N;Lee TY;Gao B;Zhang Y;Xu Y;Zhang X;Billet S;Fan X;Shiao S;Bhowmick N;Medina-Kauwe L;Giuliano A;Cui X
通讯作者：
Cui X

A multimode optical imaging system for preclinical applications in vivo: technology development, multiscale imaging, and chemotherapy assessment.

DOI：
10.1007/s11307-011-0517-z
发表时间：
2012-08
期刊：
MOLECULAR IMAGING AND BIOLOGY
影响因子：
3.1
作者：
Hwang, Jae Youn;Wachsmann-Hogiu, Sebastian;Ramanujan, V. Krishnan;Ljubimova, Julia;Gross, Zeev;Gray, Harry B.;Medina-Kauwe, Lali K.;Farkas, Daniel L.
通讯作者：
Farkas, Daniel L.

Analysis of targeted viral protein nanoparticles delivered to HER2+ tumors.

分析递送至 HER2 肿瘤的靶向病毒蛋白纳米颗粒。

DOI：
10.3791/50396
发表时间：
2013
期刊：
Journal of visualized experiments : JoVE
影响因子：
0
作者：
Hwang,JaeYoun;Farkas,DanielL;Medina-Kauwe,LaliK
通讯作者：
Medina-Kauwe,LaliK

Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer.

DOI：
10.1016/j.clbc.2015.06.001
发表时间：
2015-12
期刊：
Clinical breast cancer
影响因子：
3.1
作者：
Chung A;Choi M;Han BC;Bose S;Zhang X;Medina-Kauwe L;Sims J;Murali R;Taguiam M;Varda M;Schiff R;Giuliano A;Cui X
通讯作者：
Cui X

Resistance to receptor-blocking therapies primes tumors as targets for HER3-homing nanobiologics.

DOI：
10.1016/j.jconrel.2017.12.024
发表时间：
2018-02-10
期刊：
Journal of controlled release : official journal of the Controlled Release Society
影响因子：
0
作者：
Sims JD;Taguiam JM;Alonso-Valenteen F;Markman J;Agadjanian H;Chu D;Lubow J;Abrol R;Srinivas D;Jain A;Han B;Qu Y;Mirzadehgan P;Hwang JY;Rentsendorj A;Chung A;Lester J;Karlan BY;Gray HB;Gross Z;Giuliano A;Cui X;Medina-Kauwe LK
通讯作者：
Medina-Kauwe LK